Investors eyeing a purchase of Regeneron Pharmaceuticals, Inc. (NASD: REGN) shares, but tentative about paying the going market price of $256.05/share, might benefit from considering selling puts among the alternative strategies at their disposal.

(RTTNews.com) - Regeneron Pharmaceuticals Inc. ( REGN ) reported first quarter net income of $0.90 per share Friday morning, up from $0.11 per share in the prior year.

(By Mani) Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares are on the bullish territory on Eylea fundamentals, which continue to improve with long-term sustainability of ophthalmology related revenues.

PARIS and TARRYTOWN, N.Y., May 15, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the COMPARE and ASCERTAIN trials of sarilumab, the first fully ...

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) investors should be aware of an increase in enthusiasm from smart money in recent months.

What to watch at ASCO Regeneron Pharmaceuticals Inc (NASDAQ:REGN), perhaps best known for its highly successful wet age-related macular degeneration drug Eylea, released two promising abstracts for ASCO on monoclonal antibodies with potential ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) a biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally closed ...

Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Genomic Health Inc. (Nasdaq:GHDX), Sanofi (NYSE:SNY), Regeneron Pharmaceuticals, ...

TARRYTOWN, N.Y., May 3, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has expanded its ophthalmology portfolio by acquiring full exclusive rights to two families of novel antibodies invented at ...

Dow Jones Newswires. Regeneron Pharmaceuticals Inc.'s (REGN) stock price tripled last year, and the compensation of co-founder and Chief Executive Leonard Schleifer nearly did, too.